Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)

IF 0.3 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Rational Pharmacotherapy in Cardiology Pub Date : 2023-05-17 DOI:10.20996/1819-6446-2023-04-04

M. Ezhov, N. Akhmedzhanov, T. E. Kolmakova, A. Tyurina, A. Martynov

{"title":"Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)","authors":"M. Ezhov, N. Akhmedzhanov, T. E. Kolmakova, A. Tyurina, A. Martynov","doi":"10.20996/1819-6446-2023-04-04","DOIUrl":null,"url":null,"abstract":"Aim. To study the frequency of prescriptions of various types of lipid-lowering therapy and their effectiveness in outpatient clinical practice based on the results of a questionnaire of primary care physicians.Material and methods. The study was performed in 2022 in 75 constituent entities of the Russian Federation with the participation of 1117 doctors working in outpatient clinics. Most of the doctors had work experience of 10-20 years or more. Doctors of polyclinics (therapists and cardiologists, etc.) before the start of the study received instructions, questionnaires for filling out, developed by the National Atherosclerosis Society. The frequency of prescriptions by primary care physicians of various types of lipid-lowering therapy and their effectiveness in terms of the frequency of achieving target levels of low-density lipoprotein cholesterol (LDL-C) was studied based on the results of a questionnaire.Results. Monotherapy with statins was prescribed in 55.2% of cases, free combination of rosuvastatin with ezetimibe – in 17.2%, single pill combination of rosuvastatin with ezetimibe – in 23.2%, combination therapy with PCSK9 inhibitors – in 4.1% of cases. Target levels of LDL-C ˂ 1.8 mmol/l and ˂ 1.4 mmol/l were achieved with statin monotherapy in 42.6% and 28.2% of cases, respectively, free combination of rosuvastatin with ezetimibe – in 61.7% and 39 .5%, a fixed combination of rosuvastatin with ezetimibe – in 67.8% and 48.5%, combination therapy with PCSK9 inhibitors – in 96.8% and 92.8% of cases.Conclusion. The single pill combination of rosuvastatin with ezetimibe is more effective in achieving target levels of LDL-C compared with statin monotherapy and therapy with free combination of statin with ezetimibe. Despite the fact that the target values of LDL-C when prescribing a combination with PCSK9 inhibitors were achieved in 96.8% and 92.8% of cases, they were used quite rarely at the outpatient stage of treatment in the Russian Federation.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"44 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rational Pharmacotherapy in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20996/1819-6446-2023-04-04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim. To study the frequency of prescriptions of various types of lipid-lowering therapy and their effectiveness in outpatient clinical practice based on the results of a questionnaire of primary care physicians.Material and methods. The study was performed in 2022 in 75 constituent entities of the Russian Federation with the participation of 1117 doctors working in outpatient clinics. Most of the doctors had work experience of 10-20 years or more. Doctors of polyclinics (therapists and cardiologists, etc.) before the start of the study received instructions, questionnaires for filling out, developed by the National Atherosclerosis Society. The frequency of prescriptions by primary care physicians of various types of lipid-lowering therapy and their effectiveness in terms of the frequency of achieving target levels of low-density lipoprotein cholesterol (LDL-C) was studied based on the results of a questionnaire.Results. Monotherapy with statins was prescribed in 55.2% of cases, free combination of rosuvastatin with ezetimibe – in 17.2%, single pill combination of rosuvastatin with ezetimibe – in 23.2%, combination therapy with PCSK9 inhibitors – in 4.1% of cases. Target levels of LDL-C ˂ 1.8 mmol/l and ˂ 1.4 mmol/l were achieved with statin monotherapy in 42.6% and 28.2% of cases, respectively, free combination of rosuvastatin with ezetimibe – in 61.7% and 39 .5%, a fixed combination of rosuvastatin with ezetimibe – in 67.8% and 48.5%, combination therapy with PCSK9 inhibitors – in 96.8% and 92.8% of cases.Conclusion. The single pill combination of rosuvastatin with ezetimibe is more effective in achieving target levels of LDL-C compared with statin monotherapy and therapy with free combination of statin with ezetimibe. Despite the fact that the target values of LDL-C when prescribing a combination with PCSK9 inhibitors were achieved in 96.8% and 92.8% of cases, they were used quite rarely at the outpatient stage of treatment in the Russian Federation.

查看原文本刊更多论文

降脂治疗处方的门诊实践(根据ARGO-3研究)

的目标。目的:通过对基层医师的问卷调查，了解各类降脂治疗药物在门诊临床使用的频次及效果。材料和方法。该研究于2022年在俄罗斯联邦的75个组成实体中进行，有1117名在门诊诊所工作的医生参与。大部分医生都有10-20年以上的工作经验。综合诊所的医生(治疗师和心脏病专家等)在研究开始前收到指示，填写由国家动脉粥样硬化协会制定的调查问卷。根据问卷调查的结果，研究了基层医生使用各类降脂疗法的频率及其在低密度脂蛋白胆固醇(LDL-C)达标频率方面的有效性。他汀类药物单药治疗占55.2%，瑞舒伐他汀与依泽替米布自由联合治疗占17.2%，瑞舒伐他汀与依泽替米布单药联合治疗占23.2%，PCSK9抑制剂联合治疗占4.1%。他汀类药物单药治疗达到LDL-C小于1.8 mmol/l和小于1.4 mmol/l的目标水平分别为42.6%和28.2%，瑞舒伐他汀与依泽替米比自由联合治疗分别为61.7%和39.5%，瑞舒伐他汀与依泽替米比固定联合治疗分别为67.8%和48.5%，与PCSK9抑制剂联合治疗分别为96.8%和92.8%。瑞舒伐他汀单片联合依泽替米比他汀单药和他汀与依泽替米自由联合治疗更有效地达到LDL-C目标水平。尽管在处方联合PCSK9抑制剂时，LDL-C的目标值在96.8%和92.8%的病例中达到，但在俄罗斯联邦的门诊治疗阶段，它们很少被使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rational Pharmacotherapy in Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

1.00

自引率

50.00%

发文量

审稿时长

6 weeks

期刊介绍： The primary goals of the Journal are consolidation of information on scientific and practical achievements in pharmacotherapy and prevention of cardiovascular diseases and continuing education of cardiologists and internists. The scientific concept of the edition suggests the publication of information on current achievements in cardiology, the results of national and international clinical trials. The Journal publishes original articles on the results of clinical trials designed to study the effectiveness and safety of drugs, analysis of clinical practice and its compliance with national and international recommendations, expert s’ opinions on a wide range of cardiology issues, associated conditions and clinical pharmacology. There is a heading “Preventive cardiology and public health” in the Journal to stimulate research interest in this highly demanded area. Memories of the outstanding people in medicine including cardiology, which are of great interest to historians of medicine, are published in "Our Mentors” heading.